MIRA Pharmaceuticals submits Ketamir-2 Phase 2a CIPN protocol for IRB review after FDA feedback
MIRA•Ketamir-2 Phase 2a protocol moves to IRB review
Mira Pharmaceuticals submitted a Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral neuropathy following FDA review and feedback.
- Site initiation is targeted for Q1 2027, pending IRB clearance at a leading cancer research institution.
- The trial will test 300 mg and 600 mg doses versus placebo in a crossover design to generate initial efficacy and dose-response data.
